B+
Bull case
20%
Probability
Target price
$23.00
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
CRVS
CorvusCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
50%
Probability
Target price
$12.50
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$7.50
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-08-08
Recent news sentiment (30D)
+0.1
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+63.6
Score
AI commentary
The post-earnings tone is mixed: the company confirmed clinical enrollment progress and a Q2 2028 cash runway, but reported materially higher R&D expense and net loss. Coverage is sparse, social data are unavailable, and the packet does not provide validated analyst revisions or a clean event-window price reaction; the August 7 anchor was $13.92. This supports a cautious monitoring view rather than a high-conviction long. [#SEC-8K-2026-08-06]
RankAlpha Sentiment Codex - 2026-08-08
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-08-06eventQ2 update preserved clinical execution and runwayHigh impact
The August 6 release confirmed enrollment remained on track in the registrational Phase 3 PTCL trial and Phase 2 atopic dermatitis trial, with $215.2 million of cash, equivalents, and marketable securities supporting operations into Q2 2028. However, R&D expense rose to $16.0 million and net loss to $18.0 million year over year. [#SEC-8K-2026-08-06]
2026-09-30catalystHigher clinical spending and financing sensitivityHigh impact
The Q2 update showed R&D expense increasing from $7.9 million to $16.0 million and quarterly net loss widening from $8.0 million to $18.0 million. The disclosed runway reduces near-term stress, but continued trial expansion can increase future capital and dilution sensitivity. [#SEC-8K-2026-08-06]
2026-12-31catalystLate-2026 immunology development milestonesHigh impact
Corvus expects results from the initial China atopic dermatitis cohort late this year and plans to initiate hidradenitis suppurativa and asthma studies later in 2026. These are meaningful but clinically binary milestones. [#SEC-8K-2026-08-06]
Recommendation
N/A
No formal recommendation provided.
As of 2026-08-08 • Updated nightlySource: Internal modelMethodology